ABOUT

FSA is a network of professionals in the areas of Drug Development, Program Management, Engineering, Human Resource and Contract Administration. The group is composed of Industry, Academic, and Federal program veterans able to move programs and products forward efficiently and cost-effectively.

 

We cover critical value creation in Technology Management, Bio-Product Development, Program Management, Cost Accounting, and especially USG Funding for Biopharmaceuticals & Vaccines.  In Corporate Development: Alliance Formation and Partnering, Licensing, Market Planning, and Business Development. In support of these activities, we build simple, practical Financial Systems that your people can use and your investors will appreciate. In Finance: Guidance and the tools for securing funding on terms that best meet your needs.

Mark Logomasini
Managing Partner

Mark Logomasini is an experienced life sciences executive with a successful 25+ year track record in contract services, drug development, and medical devices. Most recently, he led the team that secured a major contract services award from the NIH. He was also the Program Manager on a BARDA-funded vaccine development program, a key member of the capture team for the $15M award.

 

Prior to founding Foothill Scientific, Mark was President/CEO and Director at Bioject Medical Technologies, a needle-free injection company sold to Inovio Pharmaceuticals in Spring 2016. In the aftermath of the FDA policy change on jet-injectors in 2011, Mark was brought in to triage the company, enabling it to survive a regulatory change that caused an 80% reduction in revenue. During his tenure Bioject was transformed into a lean, near virtual company focused on FDA permitted commercial applications, research programs, and international sales through distribution networks.

 

As a co-founder and CFO/VP Business Development of Molecular Medicine BioServices, a contract biomanufacturing and development organization (CDMO). Mark was responsible for capital structure formation, securing equity and debt financing to advance company operations. Mark managed the Business Operations group comprised of Finance and Accounting, Business Development, Project Management, Purchasing, IT, and Administration. He began working in Federal programs in 2001, leading business development activities and establishing the company as key resource in DHHS/DoD vaccine programs. When Molecular Medicine was acquired by Sigma-Aldrich in 2007 he handled the financial due diligence of the transaction and became the head of Federal Programs for S-A's SAFC contract service division. While at SAFC he served as the Medical Sector Lead for the DoD/NDIA sponsored Chem/BioDefense Acquisition Initiatives Forum for which he received an Award for Excellence from the JPEO-CBD in 2011.

 

Before Molecular Medicine, Mark built a leading west coast bioprocess equipment & engineering company, Western Separations, sold in 2000. 


Mark Logomasini has a BS in Chemical Engineering from the Missouri University of Science & Technology and MBA from the University of California, Irvine where he graduated with Honors.
He is a Certified Project Management Professional (PMP) with the Project Management Institute.

George E. Bettinger
Senior Partner

George Bettinger received his Ph.D. in Microbiology from Rutgers University and spent the next 30 years heading product development in the medical device industry, working for companies including DuPont, C.R. Bard and Mallinckrodt, where he also served for six years as plant manager for one of its manufacturing divisions and obtained certification in Regulatory Affairs.  He taught courses in Technical Project Management and How to Transfer of Products from Development to Manufacturing for the American Management Association, and is experienced in organizational management for success and profit. 

 

Dr. Bettinger joined the University of Texas Medical Branch, Galveston, Texas in 2002, where he served as the Associate Director for Product Development for the NIH funded Western Regional Center of Excellence.  He authored a successful grant proposals to NIH and led a project team made up of university, government and commercial entities to develop human and animal vaccines to protect against Rift Valley fever through Phase 2 clinical trials.  He is now Project Director at the University of Texas, El Paso on a project proposal he wrote developing an animal vaccine for protecting livestock against Rift Valley fever that is funded for 5 years by the US Agency for International Development in collaboration with Sokoine University of Agriculture, a veterinary school in Tanzania and a Moroccan manufacturing partner.  Dr. Bettinger has been successful in bridging the space between scientific discovery and the steps needed to bring that discovery to fruition in the commercial sector.

Dave Ingamells
Senior Partner

Dave Ingamells is a pharmaceutical executive with over 30 years of experience in all Chemistry, Manufacturing, and Controls (CMC) operations, including Process and Analytical Development, Bulk Manufacturing, Fill/Finish, Tableting, Facilities Design and Construction, Supply Chain Management, Validation, Metrology, Quality Assurance, and Quality Control.  Products include clinical and commercial enzymes, antibodies, viral vectors, and antibiotics. 

Dave's experience includes start-ups to large multi-national corporations, where he has implemented and managed quality systems; developed manufacturing processes; designed, constructed and commissioned clinical and commercial bulk and product manufacturing facilities; and launched commercial products.  

His most recent role was vice president of manufacturing at Vaxart, Inc; in this position, he managed all CMC functions.  Previously, he held positions at Optimer Pharmaceuticals (now Cubist/Merck), Molecular Medicine Bioservices (now SAFC Pharma/Millipore Sigma), BioMarin Pharmaceuticals, IDEC (now Biogen), and Genentech.  Mr. Ingamells holds a BS in biochemistry from San Francisco State University.

 © 2020 Foothill Scientific Associates. All Rights Reserved.